Exosome-Coated tPA/Catalase Nanoformulation for Thrombolytic Therapy

Current tissue plasminogen-based therapeutic strategies for stroke suffer from systemic side effects and poor efficacy. Hence, novel drug delivery methods are needed to overcome these shortcomings. Exosome-based drug formulations have been shown to have superior therapeutic outcomes compared to conventional systemic drug delivery approaches. In this paper, we report exosome surface-coated tissue plasminogen activator (tPA)/catalase nanoformulations with improved thrombolytic efficacy compared to free tPA, which also reduce side effects. The results showed that the tPA exosome formulations retained tPA activity, improved tPA stability, exhibited significant fibrinolysis, and showed no significant toxicity effects. Further, when combined with antioxidant enzyme catalase, the formulation was able to inhibit hydrogen peroxide-mediated oxidative stress and toxicity. Hence, exosome-based tPA/catalase nanoformulations could have the potential to offer a safer and effective thrombolytic therapy.

[1]  Abhiraj D. Bhimani,et al.  Exosome-Based Therapy for Ischemic Stroke: A Bibliometric Analysis of Current Trends and Future Directions. , 2022, World neurosurgery.

[2]  S. Park,et al.  Utility of Exosomes in Ischemic and Hemorrhagic Stroke Diagnosis and Treatment , 2022, International journal of molecular sciences.

[3]  R. Rahbarghazi,et al.  Exosomes-based therapy of stroke, an emerging approach toward recovery , 2022, Cell communication and signaling : CCS.

[4]  R. Omar,et al.  Chitosan/calcium phosphate-nanoflakes-based biomaterial: a potential hemostatic wound dressing material , 2022, Polymer Bulletin.

[5]  Liming Nie,et al.  Engineered extracellular vesicles as intelligent nanosystems for next-generation nanomedicine. , 2022, Nanoscale horizons.

[6]  Yilong Wang,et al.  Potential Role of Exosomes in Ischemic Stroke Treatment , 2022, Biomolecules.

[7]  A. Tsouknidas,et al.  Plant-Derived Extracellular Vesicles as Therapeutic Nanocarriers , 2021, International journal of molecular sciences.

[8]  P. Comoglio,et al.  Two-Chains Tissue Plasminogen Activator Unifies Met and NMDA Receptor Signalling to Control Neuronal Survival , 2021, International journal of molecular sciences.

[9]  D. Lawrence,et al.  Heparin and Arginine Based Plasmin Nanoformulation for Ischemic Stroke Therapy , 2021, International journal of molecular sciences.

[10]  M. J. Wood,et al.  Extracellular vesicles as a next-generation drug delivery platform , 2021, Nature Nanotechnology.

[11]  M. Nurunnabi,et al.  Potential Use of Exosomes as Diagnostic Biomarkers and in Targeted Drug Delivery: Progress in Clinical and Preclinical Applications , 2021, ACS biomaterials science & engineering.

[12]  Guo-Yuan Yang,et al.  Native and Bioengineered Exosomes for Ischemic Stroke Therapy , 2021, Frontiers in Cell and Developmental Biology.

[13]  Guo-Yuan Yang,et al.  Therapeutic application of exosomes in ischaemic stroke , 2021, Stroke and vascular neurology.

[14]  Junqiu Liu,et al.  Targeted nano-delivery strategies for facilitating thrombolysis treatment in ischemic stroke , 2021, Drug delivery.

[15]  Tao Li,et al.  M1 Macrophage Derived Exosomes Aggravate Experimental Autoimmune Neuritis via Modulating Th1 Response , 2020, Frontiers in Immunology.

[16]  Liang-Jun Yan,et al.  Role of Catalase in Oxidative Stress- and Age-Associated Degenerative Diseases , 2019, Oxidative Medicine and Cellular Longevity.

[17]  M. Cesari,et al.  Exosome Determinants of Physiological Aging and Age-Related Neurodegenerative Diseases , 2019, Front. Aging Neurosci..

[18]  G. Rosenberg,et al.  Neuroinflammation: friend and foe for ischemic stroke , 2019, Journal of Neuroinflammation.

[19]  J. Sluijter,et al.  Drug Delivery with Extracellular Vesicles: From Imagination to Innovation , 2019, Accounts of chemical research.

[20]  M. Chopp,et al.  Exosomes — beyond stem cells for restorative therapy in stroke and neurological injury , 2019, Nature Reviews Neurology.

[21]  M. Gutiérrez-Fernández,et al.  Role of Exosomes as a Treatment and Potential Biomarker for Stroke , 2018, Translational Stroke Research.

[22]  M. Bennett,et al.  Blood-brain barrier dysfunction and recovery after ischemic stroke , 2017, Progress in Neurobiology.

[23]  M. Chopp,et al.  MicroRNA-17–92 Cluster in Exosomes Enhance Neuroplasticity and Functional Recovery After Stroke in Rats , 2017, Stroke.

[24]  Kalyan C. Kondapalli,et al.  Na+/H+ Exchanger 9 Regulates Iron Mobilization at the Blood-Brain Barrier in Response to Iron Starvation* , 2017, The Journal of Biological Chemistry.

[25]  Shao-Hua Yang,et al.  Targeting oxidative stress for the treatment of ischemic stroke: Upstream and downstream therapeutic strategies , 2016, Brain circulation.

[26]  Zunjia Wen,et al.  Intracerebral Hemorrhage, Oxidative Stress, and Antioxidant Therapy , 2016, Oxidative medicine and cellular longevity.

[27]  V. B. Morris,et al.  Tissue plasminogen activator followed by antioxidant-loaded nanoparticle delivery promotes activation/mobilization of progenitor cells in infarcted rat brain. , 2016, Biomaterials.

[28]  F. Aqil,et al.  Bovine milk-derived exosomes for drug delivery. , 2016, Cancer letters.

[29]  Myung Soo Kim,et al.  Using exosomes, naturally-equipped nanocarriers, for drug delivery. , 2015, Journal of controlled release : official journal of the Controlled Release Society.

[30]  D. Ingber,et al.  Shear-Activated Nanoparticle Aggregates Combined With Temporary Endovascular Bypass to Treat Large Vessel Occlusion , 2015, Stroke.

[31]  D. Hermann,et al.  Enabling Technologies for Cell-Based Clinical Translation Extracellular Vesicles Improve Post-Stroke Neuroregeneration and Prevent Postischemic Immunosuppression , 2015 .

[32]  J. Mu,et al.  Grapefruit-Derived Nanovectors Use an Activated Leukocyte Trafficking Pathway to Deliver Therapeutic Agents to Inflammatory Tumor Sites. , 2015, Cancer research.

[33]  Shyam Prabhakaran,et al.  Acute stroke intervention: a systematic review. , 2015, JAMA.

[34]  Mark D. Huffman,et al.  AHA Statistical Update Heart Disease and Stroke Statistics — 2012 Update A Report From the American Heart Association WRITING GROUP MEMBERS , 2010 .

[35]  Clotilde Théry,et al.  Biogenesis and secretion of exosomes. , 2014, Current opinion in cell biology.

[36]  B. Kissela,et al.  Temporal trends in acute stroke management. , 2013, Stroke.

[37]  D. Ingber,et al.  Shear-Activated Nanotherapeutics for Drug Targeting to Obstructed Blood Vessels , 2012, Science.

[38]  Omid C Farokhzad,et al.  Targeted polymeric therapeutic nanoparticles: design, development and clinical translation. , 2012, Chemical Society reviews.

[39]  Y. Tabata,et al.  Ultrasound-responsive thrombus treatment with zinc-stabilized gelatin nano-complexes of tissue-type plasminogen activator , 2012, Journal of drug targeting.

[40]  P. Yotnda,et al.  Production and detection of reactive oxygen species (ROS) in cancers. , 2011, Journal of visualized experiments : JoVE.

[41]  V. B. Morris,et al.  Advances in stroke therapy , 2011, Drug Delivery and Translational Research.

[42]  V. Muzykantov,et al.  Catalase and Superoxide Dismutase Conjugated with Platelet-Endothelial Cell Adhesion Molecule Antibody Distinctly Alleviate Abnormal Endothelial Permeability Caused by Exogenous Reactive Oxygen Species and Vascular Endothelial Growth Factor , 2011, Journal of Pharmacology and Experimental Therapeutics.

[43]  J. Jun,et al.  Preparation of ultrasound microbubbles crosslinked to albumin nanoparticles packaged with tissue-type plasminogen activator gene plasmid and method of in vivo transfection , 2011, Journal of experimental pharmacology.

[44]  Joseph M. DeSimone,et al.  Strategies in the design of nanoparticles for therapeutic applications , 2010, Nature Reviews Drug Discovery.

[45]  S. Read,et al.  Early changes in physiological variables after stroke , 2008, Annals of Indian Academy of Neurology.

[46]  D. Atochin,et al.  Cerebrovascular Thromboprophylaxis in Mice by Erythrocyte-Coupled Tissue-Type Plasminogen Activator , 2008, Circulation.

[47]  Ulf Eriksson,et al.  Activation of PDGF-CC by tissue plasminogen activator impairs blood-brain barrier integrity during ischemic stroke , 2008, Nature Medicine.

[48]  G. Albers,et al.  Symptomatic Intracerebral Hemorrhage following Thrombolytic Therapy for Acute Ischemic Stroke: A Review of the Risk Factors , 2007, Cerebrovascular Diseases.

[49]  H. Schluesener,et al.  Nanovesicular vaccines: exosomes. , 2005, Archivum immunologiae et therapiae experimentalis.

[50]  Michael D. Hill,et al.  Thrombolysis for acute ischemic stroke: results of the Canadian Alteplase for Stroke Effectiveness Study , 2005, Canadian Medical Association Journal.

[51]  Olivier Lantz,et al.  Vaccination of metastatic melanoma patients with autologous dendritic cell (DC) derived-exosomes: results of thefirst phase I clinical trial , 2005, Journal of Translational Medicine.

[52]  Scott Hamilton,et al.  Association of outcome with early stroke treatment: pooled analysis of ATLANTIS, ECASS, and NINDS rt-PA stroke trials , 2004, The Lancet.

[53]  H S Markus,et al.  Cerebral perfusion and stroke , 2004, Journal of Neurology, Neurosurgery & Psychiatry.

[54]  Vladimir R Muzykantov,et al.  Prophylactic fibrinolysis through selective dissolution of nascent clots by tPA-carrying erythrocytes , 2003, Nature Biotechnology.

[55]  Andrew M. Demchuk,et al.  Markers of Increased Risk of Intracerebral Hemorrhage After Intravenous Recombinant Tissue Plasminogen Activator Therapy for Acute Ischemic Stroke in Clinical Practice: The Multicenter rt-PA Acute Stroke Survey , 2002, Circulation.

[56]  V. Nizet,et al.  Invasion of brain microvascular endothelial cells by group B streptococci , 1997 .

[57]  T. Böhm,et al.  Isolation and characterization of tissue-type plasminogen activator- binding proteoglycans from human umbilical vein endothelial cells. , 1996, Arteriosclerosis, thrombosis, and vascular biology.

[58]  Song Fan,et al.  Surface functionalized exosomes as targeted drug delivery vehicles for cerebral ischemia therapy. , 2018, Biomaterials.

[59]  M. Chopp,et al.  Exosome Therapy for Stroke , 2018, Stroke.

[60]  D. Crommelin,et al.  The preparation of tissue-type Plasminogen Activator (t-PA) containing liposomes: entrapment efficiency and ultracentrifugation damage. , 1995, Journal of drug targeting.